Welcome to our dedicated page for SAB BIOTHERAPEUTICS news (Ticker: SABSW), a resource for investors and traders seeking the latest updates and insights on SAB BIOTHERAPEUTICS stock.
SAB Biotherapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing a portfolio of products from its proprietary immunotherapy platform to produce targeted human polyclonal antibodies. The company leverages transchromosomic cattle genetically designed to produce human antibodies in response to an antigen. With a breakthrough therapy designation from the FDA, SAB-176 targets influenza strains, demonstrating sustained neutralization activity. The company's DiversitAb platform enables the production of fully human target-specific biologics for various therapeutic areas.
SAB Biotherapeutics (Nasdaq: SABS) has appointed Lucy To as Chief Financial Officer, effective August 12, 2024. With over 18 years of investment banking and strategic operational expertise, Ms. To will lead corporate finance, strategy, and strategic business relationships at SAB. The company is developing human anti-thymocyte immunoglobulin (hIgG) to delay the onset or progression of type 1 diabetes (T1D).
SAB's CEO, Samuel J. Reich, expressed confidence in Ms. To's ability to contribute to the company's upcoming milestones for SAB-142, their lead candidate. Ms. To, previously a Managing Director in the Healthcare Investment Banking Group at Wells Fargo, brings extensive experience in M&A, IPOs, and other equity and debt financings in the healthcare sector, with transactions totaling over $50 billion.
SAB Biotherapeutics, now rebranded as SAB BIO, has announced a new name, logo, and website updates. Despite the cosmetic changes, the company's stock symbol remains SABS. This rebranding aligns with SAB BIO's mission to address immune and autoimmune disorders, specifically type 1 diabetes (T1D), using their unique immunotherapy platform. CEO Samuel J. Reich emphasized the importance of this transformation in representing SAB BIO's focus on developing therapies to slow disease progression in T1D patients. The announcement comes ahead of their presentation at the American Diabetes Association 84th Scientific Sessions in Orlando. Additionally, the company reiterated its financial outlook for 2024 and upcoming milestones, including a Phase 1 study data readout for their lead candidate, SAB-142.
SAB Biotherapeutics (Nasdaq: SABS), a clinical-stage biopharmaceutical company, will present at the American Diabetes Association (ADA) 84th Scientific Sessions from June 21-24, 2024, in Orlando, Florida. The presentation will focus on SAB's novel immunotherapy platform, specifically its human anti-thymocyte immunoglobulin (hIgG) aimed at delaying the onset or progression of type 1 diabetes (T1D). Eric Sandhurst, Ph.D., SAB's Senior Program Manager, will present a poster on June 23, 2024, from 12:30 PM to 1:30 PM, detailing the IND-Enabling Assessment of Tolerance and Safety for SAB-142, a first-in-class fully human anti-thymocyte immunoglobulin. The poster will also be published online in the journal Diabetes® and available for viewing throughout the ADA sessions.
SAB Biotherapeutics (Nasdaq: SABS) announced the departure of its Chief Financial Officer, Michael King, effective June 4, 2024. King is leaving to become CEO at a privately-held oncology company but will continue as an advisor to SAB until the end of the year. The company has initiated a search for his permanent replacement. In the interim, Mark Conley, Vice President of Finance, will serve as Interim CFO. SAB remains optimistic about its future, focusing on expanding its clinical programs, including the delay or progression of type 1 diabetes with its hIgG therapy. The company confirmed its 2024 financial outlook and upcoming milestones, including a Phase 1 data readout for SAB-142.
SAB Biotherapeutics (Nasdaq: SABS) announced that the FDA has cleared its IND application for SAB-142, a type 1 diabetes therapy, to proceed to a Phase 1 clinical trial in the US.
SAB-142, a human anti-thymocyte immunoglobulin (hIgG), aims to delay the onset or progression of type 1 diabetes. The ongoing HUMAN trial will assess the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of SAB-142 in both healthy volunteers and participants with type 1 diabetes.
The HUMAN trial is a randomized, double-blind, placebo-controlled, single-ascending dose study, with doses ranging from 0.03mg/kg to 2.5mg/kg. The trial design mimics the MELD-ATG study, whose topline results are expected in 2025.
The third cohort has been fully enrolled and dosed without observed serum sickness. This clearance marks a significant advancement in SAB's mission to slow disease progression in type 1 diabetes patients.
SAB Biotherapeutics (Nasdaq: SABS) announced its Q1 2024 financial results and company updates. The company highlighted its focus on T1D immunotherapy, with significant progress in its SAB-142 program. Key pipeline milestones include the complete enrollment of the third cohort in its Phase 1 trial with no serum sickness observed and an impactful partnership with INNODIA. Financially, SAB reported a net loss of $4.0 million, a marked improvement from the $7.4 million loss in the previous year. Operating expenses increased, driven by higher R&D and G&A costs, reflecting intensified efforts in T1D research. Cash reserves stand at $45.2 million, anticipated to fund operations into 2026, assuming full exercise of outstanding warrants.
SAB Biotherapeutics announced the appointment of Dr. Jay Skyler to its Board of Directors. Dr. Skyler's expertise in type 1 diabetes research will benefit the company's SAB-142 program, focusing on delaying the onset of type 1 diabetes. With over five decades of experience in diabetes research, Dr. Skyler's contributions are expected to advance SAB's disease-modifying therapy.